Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Rationale:
Contrast agents are important tools for MR/CT- examinations, when it comes to diagnosing diseases. But despite their frequent use in Denmark, they are not free of serious and potentially fatal adverse reactions. Examples of this are contrast-induced nephropathy (CIN) and nephrogenic systemic fibrosis (NSF). Therefore, it is extremely important to clarify if these adverse reactions are actually directly related to the use of contrast agents or to MR/CT- examinations.
Objective:
To prospectively assess the incidence of adverse reactions of iodine-containing CT and gadolinium- based MR contrast agents in a prospective design. A control group examined without the use of contrast agent will be included, so that the study can illuminate reported adverse events related to contrast agents and CT/MR- examinations. This project will in the long term mean that, any significant and life-threatening delayed adverse reactions will be discovered earlier and hence it will be more likely to treat the patients in good time for these adverse reactions.
The following series of hypotheses will be investigated in this study:
- Renal as well as non-renal adverse reactions occurring are related to the use of contrast agent in MR-/CT-examination.
- CIN occurs in patients undergoing a MR-/CT-examination with contrast agent.
Methods:
Approvals are obtained from The Copenhagen County Committee on Biomedical Research Ethics and Danish Data Protection Agency. A total of 1600 patients will be included from Department of Radiology at Herlev Hospital, where all the MR- and CT examinations will be performed. Patients will be divided into four groups (a, b, c and d) with 400 patients in each group. Group a and c (case group) undergo respectively MR and CT examination with contrast agent While group b and d (control group) will undergo respectively MR and CT examination without the use of contrast agent. For each patient the following will be recorded: Risk factors, renal function (eGFR) before and 72 hours after MR/CT- examination as well as the incidence of immediate reactions (within 30 min.). Furthermore, patients have to answer a questionnaire 72 hours and 1 month after MR/CT- examination about the severity and frequency of adverse reactions to contrast media.
| Condition |
|---|
|
Contrast Induced Nephropathy Nephrogenic Systemic Fibrosis |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Prospective Clinical Trial to Investigate Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced) |
| Estimated Enrollment: | 1600 |
| Study Start Date: | May 2010 |
| Estimated Study Completion Date: | March 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Enhanced MR (case group)
those with an exposure to gadolinium-based contrast agent
|
|
Unenhanced MR (control group)
those without an exposure to gadolinium-based contrast agent
|
|
Unenhanced CT (control group)
those without an exposure to iodine-containing contrast agent
|
|
Enhanced CT (case group)
those with an exposure to iodine-containing contrast agent
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
The population will be selected from Herlev Hospital, Department of Radiology. Patients referred to an MR/CT-examination will be offered participation in this study.
Inclusion Criteria:
- Patients who are referred to a MR/CT-examination at Herlev Hospital, Department of Radiology
- Age > 18 years
Exclusion Criteria:
- Age < 18 years
- Patients allergic to gadolinium-based and iodine-containing contrast agents are not included in the case group
- Increased metabolism (hyperthyroidism)
- Dementia
- Pregnancy / lactation
- Patients who have undergone MR/CT- examinations within the last month prior to the actual examination
- New MR/CT-examination (enhanced and unenhanced) in the observation period (one month).
Contacts and Locations| Contact: Manal Azzouz, MSc Pharmacy | +45 44 88 43 91 | MAZZ0001@heh.regionh.dk |
| Contact: Jørgen H. Andersen, M.Sc. | +45 44 88 47 82 | j.hvidsten@heh.regionh.dk |
| Denmark | |
| Department of Diagnostic Radiology,Copenhagen University Hospital Herlev | Recruiting |
| Herlev, Denmark, 2730 | |
| Contact: Manal Azzouz, MSc Pharmacy +45 44 88 43 91 MAZZ0001@heh.regionh.dk | |
| Contact: Jørgen H Andersen, M.Sc. +45 44 88 47 82 j.hvidsten@heh.regionh.dk | |
| Principal Investigator: | Manal Azzouz, MSc Pharmacy | Department of Diagnostic Radiology,Copenhagen University Hospital Herlev |
| Study Director: | Henrik S Thomsen | Department of Diagnostic Radiology,Copenhagen University Hospital Herlev |
More Information
Publications:
| Responsible Party: | Henrik S.Thomsen, Department of Radiology, Herlev Hospital |
| ClinicalTrials.gov Identifier: | NCT01132339 History of Changes |
| Other Study ID Numbers: | H-1-2010-011 |
| Study First Received: | May 25, 2010 |
| Last Updated: | May 12, 2011 |
| Health Authority: | Denmark: Danish Dataprotection Agency |
Keywords provided by Copenhagen University Hospital at Herlev:
|
Adverse reactions to Gadolinium-based contrast agents. Adverse reactions to Iodine-containing contrast agents. |
Additional relevant MeSH terms:
|
Fibrosis Kidney Diseases Nephrogenic Fibrosing Dermopathy |
Pathologic Processes Urologic Diseases Skin Diseases |
ClinicalTrials.gov processed this record on May 16, 2013